Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10954429 | 1.00 | CYP2D6 (0.50) | CYP2D6CYP2C19MAPTPKMMMP1 | |
| SCHEMBL10084435 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19MAPTALDH1A1TP53 | |
| SCHEMBL4582880 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19TP53MMEACE | |
| SCHEMBL4582873 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19TP53MMEACE | |
| SCHEMBL6374401 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19MAPTALDH1A1TP53 | |
| SCHEMBL2559274 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19MAPTALDH1A1TP53 | |
| SCHEMBL22887450 | 0.82 | TP53 (0.41) | CYP2D6CYP2C19MAPTALDH1A1TP53 | |
| SCHEMBL28674291 | 0.80 | TP53 (0.39) | CYP2D6CYP2C19TP53MMEACE | |
| SCHEMBL29178917 | 0.80 | TP53 (0.39) | CYP2D6CYP2C19TP53MMEACE | |
| SCHEMBL29178997 | 0.80 | TP53 (0.39) | CYP2D6CYP2C19TP53MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114644651-A | Process for producing aryloxyphosphorylated amino acid ester compound | 中国人民解放军军事科学院军事医学研究院 | 2022-06-21 | — | — | CN | disclosed |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| CN-113544122-A | Cyclopentyl nucleoside analogs as antiviral agents | 詹森生物制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021030469-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10774071-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3606615-A1 | HAIR CARE COMPOSITIONS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2020-02-12 | — | — | EP | disclosed |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-01-16 | — | — | US | disclosed |
| EP-2600885-A2 | METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES | Ramot at Tel Aviv University, Ltd. (IL) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013059885-A2 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF | CEPHALON AUSTRALIA PTY LTD (AU) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013030840-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012162828-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2012-12-06 | — | — | WO | disclosed |
| EP-2478009-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | Ramot at Tel-Aviv University Ltd. (IL) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012017439-A2 | METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011033511-A1 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-03-24 | — | — | WO | disclosed |
| US-4525294-A | Amino acid mixtures, their alkali metal salts and process for preparing same | EXXON RESEARCH AND ENGINEERING CO. (US) | 1985-06-25 | — | — | US | disclosed |
| US-4069385-A | FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774071-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CYP2D6 3043/4885CYP2C19 4451/4885MAPT 3557/4885 |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 3043/4885CYP2C19 4451/4885MAPT 3557/4885 |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | PDCD1, PDCD1LG2, CD274 | CYP2D6 1842/4885CYP2C19 1407/4885MAPT 1058/4885 |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 3043/4885CYP2C19 4451/4885MAPT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.